Resistell AG
Resistell is dedicated to combating antimicrobial resistance by providing the world's fastest antibiotic susceptibility testing platform. Their innovative nanomotion technology platform delivers results in just 1 hour, enabling healthcare providers to make informed treatment decisions quickly. The company focuses on developing growth-independent, rapid diagnostic solutions that can analyze multiple drugs simultaneously, improving patient care and addressing the global challenge of antibiotic resistance.
Industries
Nr. of Employees
small (1-50)
Resistell AG
Resistell AG Hofackerstrasse 40 4132 Muttenz Switzerland
Products
Ultra-rapid nanomotion AST platform (Phenotech Multistar)
A modular, high-throughput diagnostic platform that measures nanoscale cellular motion to provide antibiotic susceptibility results in approximately 1 hour; includes sensor hardware and classification software.
Ultra-rapid nanomotion AST platform (Phenotech Multistar)
A modular, high-throughput diagnostic platform that measures nanoscale cellular motion to provide antibiotic susceptibility results in approximately 1 hour; includes sensor hardware and classification software.
Services
Research-oriented device and workflows to measure cellular nanomotion for exploratory assays, adaptable media/drug exchange and kit-based sample preparation for diverse microbiological and cellular applications.
Research-oriented device and workflows to measure cellular nanomotion for exploratory assays, adaptable media/drug exchange and kit-based sample preparation for diverse microbiological and cellular applications.
Expertise Areas
- Rapid phenotypic antibiotic susceptibility testing
- Nanomechanical sensing and sensor development
- Machine learning for diagnostic classification
- Real-time signal acquisition and processing
Key Technologies
- Nanomechanical cantilever sensors
- Nanomotion detection
- AFM-based nanomechanical sensing
- Machine learning classification
News & Updates
Antibiotic treatments are often preemptively initiated without knowing the antibiotic resistance profile of the causative pathogen. This leads to potentially inappropriate therapies. Ultra-rapid Antibiotic Susceptibility Testing (AST) is key in identifying the effective antibiotics, and here are compelling reasons for healthcare providers to prioritize it.
Antibiotic resistance changes treatable infections into significant health threats. Along with the clinical challenges comes an extra financial load, as antibiotic resistance typically adds around $1,400 to the hospital bill for treating bacterial infections, according to the CDC in the US. This steep rise indicates a concerning trend where healthcare costs climb hand-in-hand with the complexity of treating resistant strains.
Resistell, an EPFL spin-off developing rapid phenotypic antibiotic susceptibility testing (AST) solutions, announces the peer-reviewed article in the Nature Communications journal. The publication marks the completion of the company’s technology validation stage and showcases the potential of the Resistell nanomotion technology platform as a diagnostic in the fight against antimicrobial resistance (AMR).
With a remarkable 25-year journey at the forefront of healthcare innovation, Trevor brings a wealth of experience from his leadership roles across research, clinical, and corporate spheres globally. His track record of innovation, coupled with a profound understanding of the healthcare industry’s challenges and opportunities, makes him an invaluable addition to our team. Welcome aboard, Trevor!
Cellectric, Resistell and Lausanne University Hospital will collaborate on a joint Eurostars project
Cellectric, Resistell and Lausanne University Hospital will collaborate on a joint Eurostars project to build Phenotech-CF, a workflow that will reshape how antimicrobials are delivered to patients suffering from cystic fibrosis.
Novel nanomotion technology demonstrates rapid, real-time antibiotic susceptibility testing, significantly reducing analysis time for slow-growing bacteria such as Mycobacterium tuberculosis.
Antibiotic treatments are often preemptively initiated without knowing the antibiotic resistance profile of the causative pathogen. This leads to potentially inappropriate therapies. Ultra-rapid Antibiotic Susceptibility Testing (AST) is key in identifying the effective antibiotics, and here are compelling reasons for healthcare providers to prioritize it.
Antibiotic resistance changes treatable infections into significant health threats. Along with the clinical challenges comes an extra financial load, as antibiotic resistance typically adds around $1,400 to the hospital bill for treating bacterial infections, according to the CDC in the US. This steep rise indicates a concerning trend where healthcare costs climb hand-in-hand with the complexity of treating resistant strains.
Resistell, an EPFL spin-off developing rapid phenotypic antibiotic susceptibility testing (AST) solutions, announces the peer-reviewed article in the Nature Communications journal. The publication marks the completion of the company’s technology validation stage and showcases the potential of the Resistell nanomotion technology platform as a diagnostic in the fight against antimicrobial resistance (AMR).
With a remarkable 25-year journey at the forefront of healthcare innovation, Trevor brings a wealth of experience from his leadership roles across research, clinical, and corporate spheres globally. His track record of innovation, coupled with a profound understanding of the healthcare industry’s challenges and opportunities, makes him an invaluable addition to our team. Welcome aboard, Trevor!
Cellectric, Resistell and Lausanne University Hospital will collaborate on a joint Eurostars project
Cellectric, Resistell and Lausanne University Hospital will collaborate on a joint Eurostars project to build Phenotech-CF, a workflow that will reshape how antimicrobials are delivered to patients suffering from cystic fibrosis.
Novel nanomotion technology demonstrates rapid, real-time antibiotic susceptibility testing, significantly reducing analysis time for slow-growing bacteria such as Mycobacterium tuberculosis.